With ya brother (or sister; no assumptions ;) ), I can remember catching this from a guy named "retiredtechie" on an investment board back in '07-08. Added until I thought the back of the truck was full and now its ALL GOOD. Retirement will come early for AJ!!
News may be in the offing, but it may be some time in the future. Moves like yesterday may simply reflect some institutional acquisition of shares because they like what they see. The extra money does, in my opinion, indicate that some new development will be coming, but I am happy to see moves up WITHOUT news as the move helps to establish new highs and new lows which both benefit share value when the new news arrives. Exciting times for us!
With our climb to a price level that puts us "in the game" come the bashers and pumpers. Remember that responding to either does nothing but pay them a couple of cents per response. We know what we have here, let them prattle on!
Missed this announcement from 8/26. This may explain the public offering and raised funds. Termination of a credit facility means that the co. no longer has to pay for credit services. In the evolution of the co., I would imagine that some type of credit services will need to be available (the co.'s revenues are dependent on a cash flow model that is similar to retail businesses, with a wide spectrum of income sources and uncertain payment timing), but the co. is now better to negotiate terms that favor them (i.e. we park our cash with you and you give US interest on our deposits rather than having to pay for our credit).
"On August 26, 2014, that certain Amended and Restated Revolving Credit and Security Agreement, dated April 26, 2010 (as amended, the "Credit Agreement"), by and between NeoGenomics Laboratories, Inc., Path Labs, LLC ("Path Labs"), NeoGenomics, Inc., a Nevada corporation (the "Registrant," and collectively with NeoGenomics Laboratories, Inc. and Path Labs, the "Company") and CapitalSource Finance, LLC was terminated at the option of the Company. The Credit Agreement set forth the terms of a credit facility whereby NeoGenomics Laboratories, Inc. and Path Labs were borrowers and the Registrant served as guarantor thereunder. All amounts owed by the Company under such credit facility were paid in full prior to the termination of the Credit Agreement."
As I expected, the offering included sale of the full overallotment of shares offered. Always a god sign when there are more buyers than shares offered. Looking forward to news on how the co. uses the new funds. We are just starting a race that will be quite exciting!
The company has long stated that they were interested in consolidating small private labs into their company. They recently purchased a small lab in Northern CA for a song. My guess is that they have another one in their sites. This is a business sector where the small labs will eventually perish and the larger labs will continue to buy out the mid-sized labs. NEO's goal, from a business standpoint is to grow large enough to become attractive to one of the big players (IMO), or continue to grow until they are a big player in their own right.
Just some speculation here, but I've been a student of trading behavior and co. development for years. I have seen co's like ours get the initial boost we saw with the last quarter's numbers, make our run, sell off and settle (like we've done in the last week or so) and then shoot up again for no apparent reason. I wouldn't be surprised if we see a run on no news from the mid $5's to $7 or so.
The other part of this is pure marketing, OU. The are probably making themselves known to oncologists who had not previously used them.
Hey Bill! Glad to see you on the board, which probably means you've made some good money here. I see posts from Dflawed every once in a while on the MUX board, but that's it. He was such a rabid anti-Obama guy that I stopped following his posts on FB. Glad to hear from you.
If you've been for many years, at least you can smile and look at your profits. I disagree with the premises for selling however, but respect your decision, as this is different for everyone. As I look at the last year, I see the co. manage through a quite uncertain reimbursement environment, drastic overt changes in reimbursement (for the worse), and a sector that, in general, has treaded water because of the reimbursement issues. I have posted before that Steve Jones has held to his philosophy of growing the co. at the fastest possible speed without losing money, and has openly stated, to me at least, that he will forgo profit in exchange for growth, with is exactly what is happening now. The story here is about growth and innovation, and I have also stated before that we will become a REAL player in the sector when revenues come in at $300 million per year. I expect that to happen by 2018, and so long as they continue to grow, I don't give a rat's #$%$ about profit, just don't LOSE money!
Wonder if this is a premise to soften shareholders up so that when McEwen lets go of LA for a pittance (compared to what we want it to be valued for), he'll have ground to stand on.
Funny, 2 posts from me have been removed today, a reply to this idiot was one of them, but the other was reasonable. This gut showing up today is a 100% indicator that we have made a splash.
Hoping for better than that. Historically, we've risen from $1.50 at the start of 2012 to today's high, a better than 3X return. I'm looking for another 3X return in the next 2 year time frame, and, barring big changes in reimbursement, another 2X return between 2016-18 (so, yes, I want to see a share value of $30/share by 2018.) Mgmt is razor sharp, acquisitions, innovations and organic growth have all been excellent! I've not listened to the CC yet (still at work finishing up with my last patient) but reading that mgmt. has been GIVING their new prostate test away to oncologists in return for data is #$%$ BRILLIANT!! You want to establish a need for your product, GIVE IT AWAY AT FIRST!
Old friends, today was NEO's coming out party as far as the stock market is concerned. We are now ON THE MAP. Still a microcap, but its just a matter of time before that changes!
In fact, if the new products were related to HDVY, I think that NEO mgmt. would have to disclose this.
Not sure, but it may have something to do with their alliance. I've posted before that HDVY is nothing more than a shell consisting of several very smart mathematicians and geneticists who have good ideas but couldn't run a company if they had a steering wheel. It is much more likely that Dr. Albitar has come up with his own algorithms for the NextGen sequencing, and we are seeing his genius at work here.
This is classic "old school" mgmt. support of the company's public profile and exposure. Mgmt has been immaculate in their public communication, making sure the market knows EVERYTHING, good and bad about the company's developing business. They are managing this without making any foolish claims or boasts, but also leave no significant news in their pockets when the news is relevant to the business. Well played Bob and Steve!
NEO continues with their development of innovative testing. the NextGen sequencing skillset that they are developing (which is the fastest growing part of their revenue stream) continues to impress and continues to demonstrate their leadership in this space. Here's the headline:
NeoGenomics Expands Next Generation Sequencing Services and Offers 23 Different Profiles for Various Hematologic and Solid Cancers
Company Provides Widest Variety of Actionable Next-Gen Cancer Profiles.